Astrazeneca PLC (NYSE:AZN) – Investment analysts at Leerink Swann cut their Q3 2016 EPS estimates for Astrazeneca PLC in a report issued on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the brokerage will earn $0.47 per share for the quarter, down from their previous estimate of $0.56. Leerink Swann currently has a “Hold” rating and a $35.00 target price on the stock. Leerink Swann also issued estimates for Astrazeneca PLC’s FY2018 earnings at $2.06 EPS.
Other equities research analysts have also issued reports about the company. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, August 8th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Monday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research report on Saturday, June 25th. Bank of America Corp. reaffirmed a “buy” rating and issued a $36.65 target price on shares of Astrazeneca PLC in a research report on Monday, July 18th. Finally, TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Friday, July 22nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Astrazeneca PLC presently has a consensus rating of “Buy” and an average target price of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 31.12 on Monday. The company has a 50 day moving average of $33.11 and a 200 day moving average of $30.86. Astrazeneca PLC has a 52-week low of $26.97 and a 52-week high of $35.04. The stock has a market capitalization of $78.73 billion, a price-to-earnings ratio of 35.57 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. During the same period in the previous year, the firm earned $1.21 EPS. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year.
The firm also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is presently 78.29%.
A number of large investors have recently made changes to their positions in the company. Forester Capital Management LTD raised its stake in shares of Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares during the last quarter. Chubb Ltd. purchased a new stake in Astrazeneca PLC during the first quarter worth $14,080,000. Primecap Management Co. CA increased its stake in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock worth $368,453,000 after buying an additional 12,095,375 shares during the period. Stockman Asset Management increased its stake in Astrazeneca PLC by 11.3% in the first quarter. Stockman Asset Management now owns 62,700 shares of the company’s stock worth $1,766,000 after buying an additional 6,380 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Astrazeneca PLC by 5.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 202,584 shares of the company’s stock worth $5,705,000 after buying an additional 10,015 shares during the period. Hedge funds and other institutional investors own 11.39% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.